Articles by Alison Bryant
Cancers caused by human papillomavirus rose in the past decade, a fact that may irk HPV vaccine makers Merck and GlaxoSmithKline.
NIH's National Institute of Allergy and Infectious Diseases has its eye on Altravax, awarding the company $1.2 million to advance a dengue vaccine and hepatitis B therapeutic.
Pfizer has always harbored substantial goals for its pneumococcal conjugate vaccine, and the pharma giant got a leg up Tuesday when the European Commission approved the use of Prevenar 13 in older children and adolescents.
India, a country forging its way into the vaccine production business, has found itself descending into the clutches of its private sector.
Sanofi Pasteur and Sutro Biopharma will hook up to produce two undisclosed vaccine candidates.
Study: More flu vaccine benefits people with HIV
Individuals with HIV receive greater protection against the flu when given four times the normal dose of flu vaccine, a new study shows.
As a new wave of interest in HIV therapeutic vaccines hits the biotech world, a team of Spanish researchers claims to have developed such a vaccine that temporarily halts growth of the HIV virus in patients.
A typhoid vaccine recall issued back in October by Sanofi Pasteur MSD--a joint venture of pharma giants Sanofi and Merck--has resulted in a shortage of the injection in the United Kingdom.
Emergent BioSolutions snagged the exclusive right to manufacture and sell VaxInnate's flu vaccine, a product Emergent can produce quickly at high yields and low cost.
Long a financial supporter of the life sciences industry in the name of public health, the Bill & Melinda Gates Foundation is at it again, this time giving $5 million to the Johns Hopkins Bloomberg School of Public Health to promote use of oral cholera vaccine worldwide.